NCT02238262

Brief Summary

The aim of the observational study was to supplement the data on efficacy, safety and tolerability of telmisartan under daily conditions in hospitals

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,318

participants targeted

Target at P75+ for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2000

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2000

Completed
13.8 years until next milestone

First Submitted

Initial submission to the registry

September 11, 2014

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 12, 2014

Completed
Last Updated

September 12, 2014

Status Verified

September 1, 2014

Enrollment Period

7 months

First QC Date

September 11, 2014

Last Update Submit

September 11, 2014

Conditions

Hypertension

Outcome Measures

Primary Outcomes (2)

  • Change in clinic blood pressure

    up to 14 days

  • Number of patients with adverse drug reactions

    up to 14 days

Study Arms (1)

essential hypertension patients

Drug: Telmisartan

Interventions

TelmisartanDRUG
Also known as: Micardis®, low and high dose
essential hypertension patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with essential hypertension being treated in hospitals

You may qualify if:

  • Patients with diagnosis of essential hypertension
  • Minimum age of 18 years

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Hypertension

Interventions

Telmisartan

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Biphenyl CompoundsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsBenzimidazolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 11, 2014

First Posted

September 12, 2014

Study Start

May 1, 2000

Primary Completion

December 1, 2000

Last Updated

September 12, 2014

Record last verified: 2014-09